| scholarly article | Q13442814 |
| P50 | author | Gabriel N Hortobagyi | Q88225186 |
| P2093 | author name string | Xiaoping Wang | |
| Dongwei Zhang | |||
| Debu Tripathy | |||
| Peiying Yang | |||
| Chandra Bartholomeusz | |||
| Naoto T Ueno | |||
| Wendy A Woodward | |||
| James M Reuben | |||
| Yun Gong | |||
| Hiroko Masuda | |||
| Takahiro Kogawa | |||
| Bedrich L Eckhardt | |||
| Yohei Funakoshi | |||
| David A Pirman | |||
| Monica E Reyes | |||
| Adriana P Trape | |||
| P2860 | cites work | Developmental therapeutics for inflammatory breast cancer: Biology and translational directions | Q28075322 |
| Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines | Q33627158 | ||
| Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells | Q33680909 | ||
| Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer | Q33870504 | ||
| Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients | Q34996098 | ||
| Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer | Q35007782 | ||
| International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment | Q35017523 | ||
| Update on the management of inflammatory breast cancer | Q35108008 | ||
| The role of COX-2 in intestinal inflammation and colorectal cancer | Q35234704 | ||
| Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model | Q35313206 | ||
| Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma | Q35747568 | ||
| Inflammatory breast cancer: a review | Q36121844 | ||
| Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. | Q36134167 | ||
| Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. | Q36618907 | ||
| COX-2 modulates mammary tumor progression in response to collagen density. | Q36715145 | ||
| Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment | Q36956874 | ||
| Defining the molecular biology of inflammatory breast cancer | Q37097306 | ||
| Nodal promotes invasive phenotypes via a mitogen-activated protein kinase-dependent pathway | Q37259888 | ||
| Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung | Q37429876 | ||
| Nodal promotes the self-renewal of human colon cancer stem cells via an autocrine manner through Smad2/3 signaling pathway | Q37627063 | ||
| Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models | Q37696160 | ||
| Nodal signaling activates the Smad2/3 pathway to regulate stem cell-like properties in breast cancer cells | Q37743505 | ||
| Multiple drug resistance mechanisms in cancer | Q37780709 | ||
| A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. | Q38467243 | ||
| COX2 overexpression is a prognostic marker for Stage III breast cancer | Q38474547 | ||
| New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis. | Q38550876 | ||
| Plasticity underlies tumor progression: role of Nodal signaling | Q38764247 | ||
| Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer | Q39167876 | ||
| Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. | Q39379114 | ||
| Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. | Q39838070 | ||
| Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer | Q39893964 | ||
| Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy | Q40747279 | ||
| Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells | Q44137975 | ||
| Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor | Q44375278 | ||
| Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin | Q44590607 | ||
| TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. | Q53090999 | ||
| Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. | Q53279352 | ||
| Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. | Q54690251 | ||
| An inflammatory link | Q59081065 | ||
| Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program | Q69833744 | ||
| Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer | Q79918235 | ||
| P433 | issue | 40 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 67904-67917 | |
| P577 | publication date | 2017-07-04 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer | |
| P478 | volume | 8 |
| Q90161213 | Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype |
| Q93251378 | Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux |
| Q99630247 | Identification of key pathways and genes shared between Crohn's disease and breast cancer using bioinformatics analysis |
| Q63366138 | Inflammatory breast cancer biology: the tumour microenvironment is key |
| Q91783003 | Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium |
| Q49887925 | Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges |
| Q63366144 | Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer |
| Q64890079 | Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer. |
| Q90478729 | Targeted Delivery of 111In Into the Nuclei of EGFR Overexpressing Cells via Modular Nanotransporters With Anti-EGFR Affibody |
Search more.